BOOST.AI
Boost.ai, a leading conversational AI solution provider, today announced Version 12 of its platform, the first of a series of planned updates by the company to incorporate Large Language Model (LLM)-enriched features. This iteration is focused on key customer experience (CX) improvements, including content suggestion, content rewriting and accelerated generation of training data. The new update will take advantage of Generative AI to suggest messaging content to AI Trainers within the boost.ai platform, generating suggested responses and resulting in drastically reduced implementation times for new intents. With this latest release, boost.ai reinforces its commitment to researching, developing, releasing, and maintaining responsible implementations of LLM-powered, enterprise-quality conversational AI features in order to further enhance the customer experience.
ChatGPT has dominated headlines throughout 2023, yet questions about the accuracy of its underlying models, GPT-3.5 and GPT-4, persist. With an 85% accuracy rate, LLMs are a good indication of the potential of this technology in consumer-facing applications, but in their current raw state they lack the dependency for integration directly into a bank or insurance firm's systems. Boost.ai helps to resolve this issue by seamlessly integrating the predictive capabilities of LLMs with enterprise-grade control of their conversational AI platform, creating a Hybrid Natural Language Understanding (NLU) system that offers unmatched accuracy, flexibility, and cost-effectiveness. Expertly weaving together the right AI components for each task, boost.ai’s platform ensures precise and accurate answers - harnessing the benefits of LLMs, while still adhering to stringent quality assurance requirements.
“LLM technology offers great promise, but most applications just aren’t properly designed to securely and scalably support real-world businesses. With worries about accuracy or even inappropriate behavior, established institutions like banks could not risk direct access to this iteration of generative AI - until now,” said Jerry Haywood, CEO of boost.ai. “By pairing LLMs with our conversational AI, we’re able to ensure accuracy and open the door for customers in sensitive industries like financial services. We’re proud to be pioneering a way forward for businesses to harness this tech right now. It’s available for customers to use and enhance their existing solution, and to help them achieve speed to value significantly sooner whilst minimizing the risks currently dominating headlines.”
With a Hybrid NLU approach, enterprises gain the ability to combine boost.ai’s market-leading intent management, context handling, and dialogue management solutions with powerful LLM-enriched tools. Boost.ai’s existing intent engine is highly trained with guardrails in place to help guide the LLM, increasing overall accuracy and reducing the number of false positives. The end result is a chatbot that can confidently provide answers to inquiries, and a more streamlined development path that radically enhances how boost.ai customers can build scalable customer experiences for chat and voice.
“With our Hybrid NLU, we’ve been able to surpass the performance of either model on its own, providing our customers with the best of both worlds,” said Lars Ropeid Selsås, Founder of boost.ai. “Boost.ai will continue to operate at the cutting edge of AI possibility, refining our platform so that our customers are always receiving the best possible technology and service.”
On May 9th, Boost.ai co-founder, Henry Vaage Iversen and the technical team conducted a webinar highlighting the strengths of Hybrid NLU and mapping out a path for businesses to start using LLM technology to their advantage. For a recording of the full webinar, please visit: https://www.boost.ai/webinars/enhancing-cx-and-reducing-operational-costs-with-boost-ai-large-language-models
About Boost.ai
Boost.ai is a global leader in conversational AI optimized for scale. Boasting the industry's most robust intent portfolio, Boost.ai is pioneering an era of broad-scope virtual agents to deliver the most advanced and scalable technology on the market. With consistent resolution rates of 90%, Boost.ai’s market-leading virtual agent supports enterprise customers across key industries throughout the United States and Europe, including banking, insurance, telecom, retail and more. In 2021, Boost.ai was named a major player in the IDC MarketScape category, Worldwide Conversational AI Platforms for Customer Service. Key customers include Santander Bank, MSU Federal Credit Union, Aspire General Services, Tokio Marine and more. Learn more at boost.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230511005082/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom